Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Neoplasms 79Lymphoma 62Breast Neoplasms 61Prostatic Neoplasms 60Multiple Myeloma 60Lung Neoplasms 55Neoplasm Metastasis 54Ovarian Neoplasms 47Leukemia, Myeloid, Acute 47Colorectal Neoplasms 41Hematologic Neoplasms 40Melanoma 39Carcinoma, Non-Small-Cell Lung 38Pancreatic Neoplasms 31Lymphoma, Non-Hodgkin 31Glioma 31Brain Neoplasms 30Urinary Bladder Neoplasms 28Myelodysplastic Syndromes 28Sarcoma 26Carcinoma, Renal Cell 26Glioblastoma 25Fallopian Tube Neoplasms 25Neuroblastoma 23Triple Negative Breast Neoplasms 22Leukemia, Lymphocytic, Chronic, B-Cell 22Burkitt Lymphoma 21Stomach Neoplasms 19Small Cell Lung Carcinoma 19Squamous Cell Carcinoma of Head and Neck 18

Interventions

Sodium Chloride 1BNT162 Vaccine 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Severe Acute Respiratory Syndrome × 1 year × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡